What is the recommended oral and intramuscular dosing of haloperidol for an adult with psychosis or agitation, including adjustments for elderly patients, dementia-related agitation, or hepatic impairment?

Haloperidol Dosing for Psychosis and Agitation in Adults

Oral Dosing for Acute Psychosis and Agitation

For non-elderly adults with acute psychosis or agitation, initiate haloperidol at 2–5 mg orally, repeating every 2–4 hours as needed; however, doses above 1 mg provide no additional efficacy and significantly increase extrapyramidal side effects, so starting at 0.5–1 mg is preferred. 1, 2

• The standard oral dose range is 0.5–5 mg every 2–4 hours for acute agitation, though evidence demonstrates that low doses (2 mg/day) are equally effective as higher doses (8 mg/day) while producing fewer extrapyramidal symptoms and less prolactin elevation 2
• Higher initial doses (>1 mg) do not improve efficacy but markedly increase adverse effects including sedation and extrapyramidal symptoms 3
• For first-episode psychosis specifically, doses as low as 2 mg/day are effective, with evidence suggesting approximately one-third dose reduction compared to multi-episode patients 2, 4

Intramuscular Dosing for Acute Agitation

Administer haloperidol 5 mg intramuscularly for severe acute agitation in non-elderly adults, repeatable every 2–4 hours as needed. 1

• The combination of haloperidol 5 mg plus lorazepam 2 mg produces significantly greater agitation reduction at 1 hour than either drug alone 1
• IM haloperidol demonstrates rapid onset with 20 double-blind randomized trials since 1973 supporting its use, representing the largest evidence base among conventional antipsychotics 3

Elderly Patient Dosing (≥65 years)

For elderly patients with agitation or delirium, start haloperidol at 0.5–1 mg orally or subcutaneously, with a strict maximum of 5 mg per 24 hours. 3, 5, 6

• Only 35.7% of elderly patients receive the recommended 0.5 mg starting dose in clinical practice, yet low doses (≤0.5 mg) demonstrate similar efficacy to higher doses with better safety profiles 5, 6
• Frail elderly patients should begin with 0.25–0.5 mg and titrate gradually 3
• Higher doses in elderly patients increase sedation risk without reducing agitation duration or hospital length of stay 5
• Geriatric or debilitated patients require less haloperidol, with optimal response obtained through more gradual dosage adjustments and lower dosage levels 3

Dementia-Related Agitation: Critical Prerequisites

Before prescribing haloperidol for dementia-related agitation, systematically investigate and treat reversible medical causes (pain, urinary tract infection, pneumonia, dehydration, constipation, hypoxia, metabolic disturbances) and attempt non-pharmacological interventions. 3

• Haloperidol should only be used when patients are severely agitated, distressed, or threatening substantial harm to self or others after behavioral interventions have failed 3
• All antipsychotics increase mortality risk 1.6–1.7 times higher than placebo in elderly dementia patients—this must be discussed with surrogate decision-makers before initiation 3
• Use the lowest effective dose for the shortest possible duration, with daily in-person evaluation and attempt to taper within 3–6 months 3

Hepatic Impairment Adjustments

For patients with hepatic dysfunction, initiate haloperidol at 2.5–5 mg daily with more gradual titration, as liver disease reduces benzodiazepine and antipsychotic clearance. 7

• Hepatic impairment prolongs haloperidol's duration of action, necessitating careful dose selection and monitoring 7

Route-Specific Considerations

• Oral and subcutaneous routes are preferred over intramuscular when feasible 3
• Subcutaneous continuous infusion of 2.5–10 mg over 24 hours can be used for sustained control 3
• Intravenous haloperidol 0.5–1 mg is acceptable for acute delirium with agitation, not exceeding 5 mg daily in elderly patients 3

Critical Safety Monitoring

Obtain baseline ECG to assess QTc interval before starting haloperidol, as the drug causes QT prolongation, dysrhythmias, and sudden death. 3

• Monitor for extrapyramidal symptoms (tremor, rigidity, bradykinesia), falls risk, blood pressure changes, and cognitive worsening 3
• Avoid combining haloperidol with other QT-prolonging medications 3
• Do not use oral haloperidol in patients with baseline QT prolongation, concurrent QT-prolonging drugs, or prior torsades de pointes 3

Common Prescribing Pitfalls

• Do not exceed 5 mg per day in elderly patients—higher doses provide no benefit and significantly increase adverse effects 3, 5
• Avoid benzodiazepines as first-line for agitated delirium (except alcohol/benzodiazepine withdrawal), as they increase delirium incidence and duration and cause paradoxical agitation in ~10% of elderly patients 1, 3
• Do not initiate haloperidol without first addressing reversible medical causes of agitation 3
• Avoid indefinite continuation—reassess need at every visit and taper when no longer indicated 3